ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

Featured News

  • 16 Oct 2014 7:45 PM | Christopher McCoy

    For those who work in acute care hospitals, given the recent events in Dallas, TX, would encourage review of the CDC website for the latest and most reliable information on Ebola virus and the response needed at the local level particularly at referral centers.  There are also links to the potential for IND use of ZMapp.  The CDC’s Clinician Outreach and Communication Activity (COCA) program continues to organize webinars.  The American Hospital Association will be conducting a webinar program tomorrow October 17th at 11am EST,

  • 13 Oct 2014 11:37 AM | Christopher McCoy

    The U.S. Food and Drug Administration approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.  It is the first approved regimen that is interferon or ribavirin sparing.

    For more information, please visit: Harvoni.

  • 09 Oct 2014 7:27 PM | Christopher McCoy

    Feb. 2-3, 2015. This two-day training course is designed for physicians of infectious diseases, healthcare epidemiologists, microbiologists, pharmacists, and other healthcare providers who are involved with creating, implementing, or improving an antimicrobial stewardship program for their healthcare institution. It meets the training needs set out in California Bill SB 1311 for Stewardship training. For more information and to register for the conference, visit the Webpage

  • 28 Sep 2014 7:47 AM | Christopher McCoy

    After initially issuing a complete response and denial of the individual drugs in 2013 to Gilead, the FDA approved the drugs last week.  

  • 25 Sep 2014 2:51 PM | Christopher McCoy

    Last week the White House announced the President’s Council of Advisors on Science and Technology (PCAST) release of a report to the President, Combating Antibiotic Resistance. The report was released simultaneously with a National Strategy on Combating Antibiotic Resistant Bacteria as well as with a Presidential Executive Order, emphasizing to the Nation the importance of addressing this growing challenge.

  • 24 Sep 2014 3:57 PM | Christopher McCoy

    2014 NFID Fall Clinical Vaccinology Course scheduled for November 7-9, 2014 at the Houston Marriott at the Texas Medical Center in Houston, TX.

    Early registration closes on September 29, 2014! Register before then to save $100.

    Earn up to 19.75 hours of continuing education credit (CME, CNE, CPE).

    Please click here for details and registration.

  • 20 Sep 2014 11:07 AM | Christopher McCoy

    CLSI 2015 Antimicrobial Susceptibility Testing Update
    February 4, 2015 or February 5 1015
    1:00 - 2:30 PM ET 3:00 - 4:30 PM ET
    Registration Deadline: February 2, 2015

    Early Bird Pricing Available!
    Register online by 1/7/15 to qualify.

    DESCRIPTION
    Each January, CLSI updates standards for antimicrobial susceptibility testing (AST). It is important for clinical laboratories to incorporate the new recommendations into routine practice to optimize detection and reporting of antimicrobial resistance. In January 2015, the annual update of the M100 tables (CLSI document M100-S25) will publish. In addition, there will be updates to the standards that describe performance of disk diffusion and MIC tests in versions M02-A12 and M07-A10, respectively. Some highlights for 2015 include introduction of the carbaNP test for carbapenemases and expanded recommendations for quality control testing. These changes and several other new recommendations found in M100-S25, M02-A12 and M07-A10 will be
    discussed. In addition to the webinar, an optional postprogram self-assessment
    will be provided that will allow individuals to assess their knowledge regarding the
    most important AST and reporting issues for 2015. Laboratories can use this
    feature to augment competency assessment requirements for their staff.

    FACULTY
    Janet A. Hindler, MCLS MT(ASCP), Sr. Specialist, Clinical Microbiology, UCLA Health System, Los Angeles, CA

    AUDIENCE
    This intermediate-level program is appropriate for laboratory professionals working in clinical and academic settings.

    CONTINUING EDUCATION is available

    REGISTRATION
    Registration fee is per site for one connection to the live program with unlimited
    attendance (and CEUs) for everyone AND unlimited access (and CEUs) to the archive program for 6 months

    Early Bird Special $110: Register online by January 7, 2015
    Regular fee: $125 when you register by registration form or online after January 7, 2015

    Site facilitator must register online at www.aphl.org/courses/pages/588-950-15.aspx. Having difficulty with the online registration process? Please email registrar@aphl.org or call 240.485.2727 from 8:00 AM to 4:30 PM ET
    . ET.

  • 26 Aug 2014 10:01 AM | Christopher McCoy

    Triumeq (ABACAVIR SULFATE;DOLUTEGRAVIR;LAMIVUDINE)

    was approved by the FDA on August 22nd, marking the second once daily integrase combination approved but without the drug interactions and intolerances associated with cobicistat in the QUAD pill.  Information from the SINGLE trial is available from the CROI 2014 meeting and a review of the agent in N Engl J Med. 2013;369:1807-1818.

  • 07 Aug 2014 8:34 AM | Christopher McCoy

    After initial rejection in 2008, Oritavancin is approved today with the gateway indication for acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), various Streptococcus species and Enterococcus faecalis.  Oritavancin now joins dalbavancin, approved May 2014 and tedizolid approved June 2014 for similar indications, all with unique profiles.  The data exceeds this space so for more information, you can always review the CDER brief but objective review for dalbavancin and tedizolid. Review papers from the 2000s for oritavancin basics. Three new drugs courtesy of the GAIN act. Looking forward to the new beta lactamase inhibitor and cephalosporin for new gram negative pathogen options.

  • 06 Aug 2014 9:57 AM | Christopher McCoy

    BACK TO THE PATIENT:
    RE-FOCUSING ANTIMICROBIAL
    STEWARDSHIP

    SEPTEMBER 6, 2014
    7:00 AM - 9:00 AM
    MEETING ROOM 206
    WALTER E. WASHINGTON CONVENTION CENTER
    801 MT VERNON PLACE NW
    WASHINGTON, DC


    PRESENTERS
    ANTHONY D. HARRIS, MD, MPH
    Professor of Medicine
    University of Maryland Medical Center, Baltimore, MD

    This session will educate the clinician on how to identify patient centered outcomes to measure the performance of an ASP, including the feasibility of capturing such measures and consideration of the changing healthcare landscape in the era of healthcare reform.


    CRAIG A. MARTIN, PHARMD, BCPS
    Clinical Associate Professor
    Department of Pharmacy Practice and Services
    University of Kentucky College of Pharmacy, Lexington, KY

    This session will inform the clinician on various types of quasiexperimental studies, including the advantages and disadvantages of each type and consideration of variability in resource availability.


    For more information and to register, view the summary.

Membership gives you more

  • Access exclusive opportunities
  • Connect with colleagues
  • Attend networking events

JOIN TODAY


Society of Infectious Diseases Pharmacists • 403 W. Saint Charles, Suite B, Lombard, IL 60148
(331) 248-7888 sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software